Active — Not RecruitingNot Applicable

Shared Decision Making on Radiation Dose for Lung Malignancies

Denmark40 participantsStarted 2021-11-12

Plain-language summary

A Patient Decision Aid (PtDA) is developed during a workshop in close collaboration with selected patients. The PtDA is subsequently used in the consultation between patient and physician to facilitate their shared decision on the dose of stereotactic body radiation therapy (SBRT) for lung tumors located less than 1 cm from the thoracic wall. Hypothesis: The use of a PtDA will increase the extent of Shared Decision Making (SDM) during the consultation and result in patients being more directly involved in the planning of their treatment.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥ 18 years * Histologically confirmed or high probability of non-small cell lung cancer, or metastasis from other cancer, located ≤ 1 cm from the thoracic wall. High probability refers to consensus on the diagnosis at the local multi-disciplinary lung tumor conference. * Eligible for stereotactic body radiation therapy in ablative doses (i.e. 66/45 Gy in 3 fractions) following national guidelines (2). * Can read and understand Danish. * Written and orally informed consent. * Performance status 0-2 * Life expectancy \> 6 months assessed by the physician during the consultation. Exclusion Criteria: * Previous radiation therapy in the thoracic region (lung, breast or mediastinum), if it is not possible to produce a new radiation plan of 66 or 45 Gy in 3 fractions that considers previous radiation therapy and still complies with all constraints, including dose to the thoracic wall. Previous surgery in the thorax is allowed. * Mental or social conditions preventing full understanding of the information or the planned treatment and follow-up.

What they're measuring

The extent of shared decision making in the consultation between patient and oncologist as measured by the OPTION tool

Timeframe: During the one hour primary consultation.

Trial details

NCT IDNCT04940936

SponsorVejle Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-01-30